BD Q1 fiscal 2026 revenue rose 1.6% to $5.3 billion; adjusted EPS fell to $2.91
BD reported fiscal first-quarter revenue of $5.3 billion, up 1.6% as reported, and GAAP diluted EPS of $1.34, up from $1.04 a year earlier. Adjusted diluted EPS fell 15.2% to $2.91 from $3.43, so the headline measures moved in different directions. The company said its combination with Waters Corporation of the Biosciences and Diagnostic Solutions business is expected to close on the same day, and it gave New BD fiscal 2026 adjusted diluted EPS guidance of $12.35 to $12.65.
Key points
- Revenue was $5,252 million, up 1.6% as reported and 0.4% on a currency-neutral basis; New BD revenue rose 2.5% on that basis.
- Adjusted diluted EPS was $2.91, down from $3.43 (down 15.2%); GAAP diluted EPS was $1.34, up from $1.04.
- The Biosciences and Diagnostic Solutions combination with Waters Corporation was expected to close February 9, 2026.
- Fiscal 2026 New BD adjusted diluted EPS guidance is $12.35 to $12.65; revenue growth guidance is low single-digit and unchanged.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:42 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 09, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.